Prostate Cancer Treatment: The Role of Gleason Score and Low PSA Levels in Early Stages

Strategic approaches to prostate cancer treatment have changed substantially recently. Innovative diagnostic and treatment methods have increased hope in fighting the disease. Until now, prostate cancer studies focused mainly on advanced and metastatic patients. New discoveries, however, revealed that chemotherapy in early stages after radiotherapy and hormonal treatment prolongs survival.
More importantly, prostate cancer types were understood to vary as breast cancer types do, requiring early-stage treatments to be questioned. Broader definitions of prostate cancer and the increasing importance of Gleason score, the classification system determining disease aggressiveness, added a new dimension to treatment.
A new study states that early-stage prostate cancer with a Gleason score of 8-10 and low PSA levels follows a more aggressive course. This interesting finding shows that low PSA can sometimes adversely influence the disease course. In particular, early-stage patients with high Gleason scores and PSA of 2.5 ng/ml or less were found to have more aggressive disease and shorter survival.
In the future, chemotherapy is also expected to be added to surgery and local treatments in early-stage prostate cancer. This resembles an approach used in biologically aggressive breast cancer. These important advances in prostate cancer, a common cancer type, are predicted to bring hope and healing to millions. Better understanding of the disease provides more effective management and treatment. Every new finding and development is a step in patients' favor and increases the satisfaction of sharing this information.
Sources
Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.